Neurocognitive, psychological, and psychosocial assessement
Neurocognitive, psychological, and psychosocial assessement: * A neuropsychological assessment including:
* Administration of standardized psychometric tests.
* Administration of parental and self-report questionnaires.
* A semi-structured neuropsychological interview about academic and developmental history, and current difficulties.
* A psychological assessment including two clinical interviews:
* The first with the child alone.
* The second with at least one parent (ideally both) and the child.
Study summary
Primary immunodeficiencies (PIDs) are a large group of genetic diseases of the immune system with highly variable clinical presentations. Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatments offered to some patients with PIDs. It is a curative but particularly demanding treatment, potentially life-threatening, requiring several months of hospitalization, prolonged limitations in social interactions for the patient, and impacting the entire family unit. The short-term complications of HSCT are numerous and well-known. However, few studies describe the long-term psychological and cognitive complications of HSCT, particularly in the context of PIDs. The few published studies in children concern patients transplanted for hematological malignancies, a context very different from that of primary immunodeficiencies.
This study is a pilot research project focusing on the multidimensional assessment of the neurocognitive, psychological, and psychosocial functioning of children between 6 and 8 years old who have received allogeneic hematopoietic stem cell transplantation for primary immunodeficiency for at least 2 years. These stringent criteria aim to limit biases related to the diversity of ages at which care is provided.
Eligibility
Sex
ALL
Min age
6 Years
Max age
8 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients who underwent allogeneic transplantation for a primary immunodeficiency at Necker Hospital, regardless of the genetic diagnosis, and at least 2 years post Allogeneic hematopoietic stem cell transplantation.
* Chronological age at the time of evaluation between 6 years and 8 years 11 months.
* Holders of parental authority and children or adolescents or adults' patients informed and consenting to participate in the study
Exclusion Criteria:
* Child transplanted for a condition other than the primary immunodeficiency or at a different center.
* Presence of an associated acquired or genetic neurological condition, independent of the PID, likely to significantly impair cognitive development.
* Severe uncorrected sensory impairment (auditory or visual) rendering the cognitive assessment uninterpretable.
* Refusal to participate by the child or those with parental authority.
* Child not fluent in French or not proficient enough in French to complete the cognitive tests and questionnaires.
* Profound intellectual disability.
Primary outcome measure(s)
Standardized measure of intelligence quotient — Time 0 Assessment of global intellectual functioning using the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) or the Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), according to the participant's age.
The Full-Scale IQ is derived from five cognitive indices:
* Verbal Comprehension Index (VCI)
* Visual Spatial Index (VSI)
* Fluid Reasoning Index (FRI)
* Working Memory Index (WMI)
* Processing Speed Index (PSI) Each index is standardized with a mean of 100 and a standard deviation (SD) of 15. Individual subtests have a mean score of 10 (SD 3).
Higher scores indicate better cognitive performance.
Interpretation of IQ scores:
* \<70: Extremely low (clinically impaired)
* 70-79: Borderline
* 80-89: Low average
* 90-109: Average
* 110-119: High average
* 120-129: Superior
* ≥130: Very superior
For subtest scaled scores:
* 15-19: Very high
* 12-14: High average
* 9-11: Average
* 7-8: Low average
* 6: Borderline
* 1-5: Impaired
Trial sites (1)
Facility
City
Region
Status
Hôpital Necker-Enfants Malades
Paris
France
Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
